Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
GlobalData on MSN15h
Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...
ENDPOINTS NEWS17h
Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
eLife1d
Iridescent structural coloration in a crested Cretaceous enantiornithine bird from Jehol Biota
The referred specimen of the enantiornithine bird Shangyang sp. (IVPP V 26899) was recovered near La-Ma-Dong Village in Jian-Chang County, within the Jiufotang Formation (dated ∼120 Ma). It can be ...
Hosted on MSN3d
Five cats taken to Portland animal hospital with suspected bird flu
Five more possible cases of bird flu in cats all came from the same home in Portland, officials said. Two of those cats have ...
Why Blue Bird (BLBD) Remains a Solid Choice Despite Policy Uncertainty
Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...
Blue Bird: No Floor In Sight - Pending Further Policy Clarity (Rating Downgrade)
BLBD remains volatile despite strong earnings, federal funding uncertainties, and revised EV sales guidance. Explore more ...